Jakarta, CNN Indonesia —
Minister of SOEs Erick Thohir say therapeutic drugs covid-19 made by PT Indofarma (Persero) Tbk Ivermectin has obtained a distribution permit from the Food and Drug Supervisory Agency (BPOM). The drug is now in the production stage with an expected capacity of 4 million per month.
“We would like to convey about the drug Ivermectin, which Alhamdulillah today has issued a distribution permit from the BPOM, and we continue to communicate incentives to the Ministry of Health according to the recommendation that this drug must be approved by a doctor for daily use,” he said in a virtual press conference, Monday (21 /6).
Erick claims Ivermectin is a COVID-19 therapeutic drug that can reduce and anticipate transmission. The medicinal properties, he said, have also been reviewed in a number of health journals. “We are conducting a stability test, because of that our Ivermectin has started production,” he said.
The price is also considered quite cheap with Rp. 5,000-Rp. 7,000 thousand per tablet. While its use, explained Erick, for light therapy, it is enough to drink on the first, third and fifth days with 2-3 pills per day.
Meanwhile, if the therapy is being recommended to take the drug five days in a row. “For the moderate category, the first, third and fifth days are regularly five points. But this is not a drug but part of therapy,” he said.
Erick hopes that the procurement of drugs through state-owned subsidiaries can help make it easier for people to get cheap drugs, especially in remote areas.
“For the record, we hope that we are in accordance with our main duties and functions, supporting the so-called Micro PPKM so that the condition of these smallest areas can get cheap drug facilities, not depending on very expensive drugs but these become cheap drugs,” he added.
In addition, the drug is also expected to help reduce the burden on hospitals in treating COVID-19 patients. “We know that we from SOEs also see the conditions in the state-owned hospitals themselves are in quite apprehensive conditions. Therefore we are looking for solutions, one of which is therapy,” he said
(hrf/age)
– .
